Live Breaking News & Updates on Applied Proteomics
Stay updated with breaking news from Applied proteomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
E-Mail Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. For this study, the researchers are infecting ACE2 animals intranasally with SARS-CoV-2 and following them for up to seven days after infection. As part of the second study, they are working to determine the survival advantage conferred by a therapeutic if an alternate course or dosing strategy needs to be followed. Again, the researchers are following the animals for up to seven days after infection. ....
E-Mail IMAGE: Lance Liotta, MD, PhD, study PI, and George Mason University College of Science CAPMM co-founder and co-director. view more Credit: Evan Cantwell, George Mason University A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments. George Mason University s College of Science announced an exciting $1.33 million collaboration with Rutgers Cancer Institute of New Jersey and Mason s Center for Applied Proteomics and Molecular Medicine (CAPMM) which taps cancer research diagnostics and treatment strengths within the medical facilities and CAP/CLIA laboratory respectively of the two regional powerhouses. ....
Credit: Copyright: George Mason University 2021 Mason scientists employ a rapid-result, saliva-based test that significantly expands testing capacity, and an antibody test that can track vaccine response. George Mason University announces it is introducing a rapid-result, saliva-based COVID-19 test that will greatly expand testing capabilities on its campuses this spring. The effort, led by Mason s faculty, is part of a comprehensive program to better track and control the virus on campus. Mason scientists, who are pushing the boundaries of technologies that are keeping Mason s campuses safe, are also developing an antibody test that can track a body s response to the virus and vaccine. See more in this video. ....